HYDROMETHYLTHIONINE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H19N3S
Molecular Weight	285.407
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CN(C)C1=CC2=C(NC3=C(S2)C=C(C=C3)N(C)C)C=C1

InChI

InChIKey=QTWZICCBKBYHDM-UHFFFAOYSA-N

InChI=1S/C16H19N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10,17H,1-4H3

HIDE SMILES / InChI

Molecular Formula	C16H19N3S
Molecular Weight	285.407
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

L-MTX is a second-generation tau protein aggregation inhibitor. It acts by reducing levels of aggregated or misfolded tau proteins, which are associated with the progressive neurodegeneration. It is currently under development for the treatment of Alzheimer’s disease.

Originator

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Tau protein aggregation 3	Inhibitor 8,297		0.12 µM [Ki]

PubMed

Show entries

Title	Date	PubMed
Tau-aggregation inhibitor therapy for Alzheimer's disease.	2014 Apr 15	24361915
Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.	2015 Apr 24	25759392
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.	2016 Dec 10	27863809